Viscusi Eugene R
a Thomas Jefferson University, Acute Pain Management, Department of Anesthesiology , US 111 S. 11th Street, Suite G8490, Philadelphia, PA 19107, USA +1 21 59 55 61 61 ; +1 21 59 23 55 07 ;
Expert Opin Drug Saf. 2015;14(12):1801-3. doi: 10.1517/14740338.2015.1089232. Epub 2015 Oct 5.
The need for better post-surgical pain management continues to be unmet, despite clinicians' awareness and concern for many years. Opioids remain the standard of care because of their analgesic efficacy; however, opioid use is often associated with adverse effects and poor patient outcomes. Multimodal analgesic regimens have recently been endorsed as a way to provide adequate post-surgical pain control while reducing opioid consumption. Liposome bupivacaine is a liposomal formulation of bupivacaine indicated for a single administration into the surgical site. Based on the available clinical trial data compiled to date, as well as the author's review of publicly available post-marketing safety information, liposome bupivacaine may be a viable addition to currently available therapeutic options for post-surgical analgesia while reducing potential risks associated with use of opioid analgesics, and may represent a useful addition to the multimodal analgesic modalities currently used for post-operative pain management. The potential for its use in other areas is also being investigated. The purpose of this review is to examine the currently available post-marketing safety information on liposome bupivacaine.
尽管临床医生多年来一直有所认识和关注，但术后疼痛管理仍未得到充分满足。由于阿片类药物的镇痛效果，它们仍然是护理的标准；然而，阿片类药物的使用往往与不良反应和患者预后不良有关。多模式镇痛方案最近被认可为一种在减少阿片类药物消耗的同时提供充分术后疼痛控制的方法。脂质体布比卡因是布比卡因的脂质体制剂，适用于单次注射到手术部位。根据迄今为止汇编的现有临床试验数据，以及作者对公开可用的上市后安全信息的审查，脂质体布比卡因可能是目前术后镇痛治疗选择的可行补充，同时减少与使用阿片类镇痛药相关的潜在风险，并且可能是目前用于术后疼痛管理的多模式镇痛方法的有用补充。其在其他领域的应用潜力也正在研究中。本综述的目的是研究目前关于脂质体布比卡因的上市后安全信息。
